Enanta Pharmaceuticals Valuation Multiples

Enanta Pharmaceuticals Overview

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Founded

1995

HQ

Employees

120

Website

enanta.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $66M

EBITDA: ($61M)

EV

$277M

Valuation Multiples

Multiples.vc

Start free trial

Enanta Pharmaceuticals Financials

Enanta Pharmaceuticals reported last 12-month revenue of $66M and negative EBITDA of ($61M).

In the same LTM period, Enanta Pharmaceuticals generated $66M in gross profit, ($61M) in EBITDA losses, and had net loss of ($71M).

Enanta Pharmaceuticals P&L

In the most recent fiscal year, Enanta Pharmaceuticals reported revenue of $65M and EBITDA of ($71M).

Enanta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals has current market cap of $406M, and enterprise value of $277M.

Enanta Pharmaceuticals' stock price is $13.98.

Enanta Pharmaceuticals Valuation Multiples

Enanta Pharmaceuticals trades at 4.2x EV/Revenue multiple, and (4.5x) EV/EBITDA.

Enanta Pharmaceuticals Financial Valuation Multiples

As of April 11, 2026, Enanta Pharmaceuticals has market cap of $406M and EV of $277M.

Equity research analysts estimate Enanta Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Enanta Pharmaceuticals has a P/E ratio of (5.7x).

Enanta Pharmaceuticals Margins & Growth Rates

Enanta Pharmaceuticals' revenue in the last 12 month declined by (2%).

Enanta Pharmaceuticals' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.3M for the same period.

Enanta Pharmaceuticals' rule of 40 is (73%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Enanta Pharmaceuticals' rule of X is (73%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Enanta Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Enanta Pharmaceuticals M&A Activity

Enanta Pharmaceuticals acquired XXX companies to date.

Last acquisition by Enanta Pharmaceuticals was on XXXXXXXX, XXXXX. Enanta Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Enanta Pharmaceuticals Investment Activity

Enanta Pharmaceuticals invested in XXX companies to date.

Enanta Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Enanta Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).